Behavioral health company LifeStance Health (NASDAQ: LFST) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue rising 25.3% year on year to $455.9 million. In addition, next quarter’s revenue guidance ($456 million at the midpoint) was a positive surprise, coming in 3.9% above analysts’ consensus estimates. Its GAAP profit of $0.06 per share was $0.03 above analysts’ consensus estimates.
For more on LifeStance Health Group, read our full research report, available free.
LifeStance Health Group (LFST) Q3 2026 highlights:
- Revenue $455.9 million vs S&P analysts’ consensus estimates of $431.7 million (25.3% year-on-year growth, 5.6% beat)
- EPS (GAAP) $0.06 vs analysts’ consensus estimates of $0.03 ($0.03 beat)
- Adjusted EBITDA $68.36 million vs analysts’ consensus estimates of $55.31 million (15% margin, 23.6% beat)
- Revenue guidance $456 million at the midpoint for Q4 2026, above analysts’ consensus estimates of $438.7 million
- EBITDA guidance $246 million at the midpoint for the full year, above analysts’ consensus estimates of $228.3 million
- Operating margin 7.3%, up from 2% in the same quarter last year
- Free cash flow margin 4.9%, similar to the same quarter last year
- Sales volumes rose 10.8% year on year, in line with the same quarter last year
- Market capitalization $5.43 billion
“The team delivered a tremendous quarter, with execution across the business driving results that once again exceeded our expectations,” said Dave Bourdon, CEO of LifeStance. “The strong momentum gives us the confidence to further raise our full-year 2026 outlook across all financial metrics, while our positive patient outcomes, most recently across TMS and Spravato, reflect our commitment to clinical excellence. At the same time, the investments we are making in our platform, including the implementation of our new EHR, are positioning LifeStance for continued success and scale over the long term.”
Revenue growth
Reviewing a company’s long-term revenue performance reveals insights into its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, LifeStance Health Group grew its revenue at a strong 23% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers.
Long-term growth matters the most, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. LifeStance Health Group’s annualized revenue growth of 17.9% over the last two years is below its five-year trend, but the results still suggest healthy demand. 
The company’s number of clinicians, which reached 8,863 in the latest quarter, provides insight into its revenue dynamics. Over the last two years, LifeStance Health Group’s clinician count grew an average of 10.3% year on year. Revenue growth outpaced this metric, indicating that price increases contributed to growth. 
This quarter, LifeStance Health Group reported strong year-on-year revenue growth of 25.3%, and its $455.9 million of revenue topped Wall Street’s consensus estimates by 5.6%. Management is guiding for a 19.3% year-on-year increase in revenue next quarter.
Looking further ahead, sell-side analysts expect revenue to grow 12.7% over the next 12 months, according to S&P, a deceleration versus the last two years. Still, this projection is healthy and implies the market expects success for its products and services.
Adjusted operating margin
LifeStance Health Group was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 4.1% was weak for a healthcare business.
On the positive side, LifeStance Health Group’s adjusted operating margin rose by 12 percentage points over the last five years, as its revenue growth provided operating leverage. More recently, the company’s trajectory has remained intact, with its margin increasing by 8.1 percentage points over two years.
In Q3, LifeStance Health Group generated an adjusted operating margin of 11.2%, up 3.9 percentage points year on year. This improvement shows it was more efficient.
Earnings per share
Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth. For example, a company could inflate its revenue through excessive spending on advertising and promotions.
LifeStance Health Group’s full-year EPS turned positive over the last five years. That improvement marks a critical turning point for the company.
In Q3, LifeStance Health Group reported EPS of $0.06, up from $0 in the same quarter last year. This result came in well above analysts’ consensus estimates, a favorable outcome for shareholders. Over the next 12 months, Wall Street expects LifeStance Health Group’s full-year EPS to grow 12.1% from $0.19 to $0.21, according to S&P.
Key takeaways from LifeStance Health Group’s Q3 results
LifeStance Health Group delivered a solid quarter, with EPS topping Wall Street’s estimates and next-quarter EBITDA guidance coming in well above analysts’ consensus estimates. Shares surged 6% to $15.06 immediately after the report.
LifeStance Health Group had a positive quarter, but one earnings result doesn’t necessarily make the stock a buy. It’s important to consider its valuation and business quality as well as the latest results. For more on these factors, read our full research report here (it’s free).
